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Abstract 
 
Depression following psychosis is common and can impact negatively on individuals’ quality 
of life. This study conducted post-hoc analyses on 14 participants with psychosis from a 
larger randomised controlled trial who presented with clinically important levels of 
depression at baseline. Eight of the participants received Acceptance and Commitment 
Therapy (ACT), whilst the remaining six individuals received treatment as usual (TAU). The 
focus was on investigating clinically significant change in outcome measures between 
baseline and 3-months post-baseline in the participants. Participants completed measures 
assessing depression and anxiety (HADS), psychosis symptoms (PANSS) and psychological 
inflexibility (AAQ-II) between baseline and at 3-month post-baseline assessments. Odds ratio 
analysis indicated that participants receiving ACT, compared to TAU, were 15 times more 
likely to achieve clinically significant decreases in depression scores (Fisher’s Exact Test p = 
0.05). Differences between the ACT and TAU groups in clinically significant changes in 
anxiety, psychological inflexibility, positive symptoms, negative symptoms and general level 
of psychopathology were not statistically significant. The study provides tentative support for 
the use of ACT to treat depression emerging in the context of psychosis. 
 
Introduction 
 
The experience of psychosis is associated with increased levels of depression (Birchwood et 
al., 2000).  Those who develop depression appraise psychosis as a humiliating threat to their 
future status that will lead to the loss of a sense of personally valued social roles and goals 
(Birchwood et al., 2006; Birchwood et al., 2000). Consistent with these threat appraisals, 
internalised stigma and shame are key features evident in depression occurring in the context 
of schizophrenia (Gumley et al., 2010). Prevalence studies show that several months after an 
acute episode of psychosis, rates of depression can be up to 50% of cases (Whitehead et al., 
2002; Birchwood, 2003). Depression has been identified as a major factor contributing to 
poor quality of life in individuals with psychosis (Saarni et al., 2010; Meijer et al., 2009). 
 
There is limited evidence supporting the use of pharmacological and psychological 
interventions for depression in the context of schizophrenia (Whitehead et al. 2002; Wykes et 
al., 2008). Although effective at treating positive symptoms, Cognitive Behavioural Therapy 
for psychosis (CBTp) is less effective for treating emotional dysfunction associated with 
psychosis such as depression, hopelessness and suicide risk (Birchwood, 2003; Wykes et al., 
2008; Tarrier et al., 2006). Whereas traditional CBTp tends to emphasize the importance of 
changing the content of these appraisals, increasing research attention is being directed 
toward the benefits of applying acceptance-based approaches to the psychological treatment 
of psychosis (Tai & Turkington, 2009). Acceptance-based approaches place less emphasis on 
altering the content of cognitions in favour of focusing on how individuals relate to these 
cognitions. One possibility that warrants research attention is whether these newer approaches 
provide alternative options for conceptualising and treating depression in the context of 
psychosis. 
 
Acceptance and Commitment Therapy (ACT) conceptualises psychological suffering as being 
largely caused by experiential avoidance, cognitive entanglement, and associated 
psychological rigidity that impedes people’s ability to take behavioural steps that are 
consistent with their core values (Hayes & Smith, 2005). Preliminary findings with non-
psychotic populations provide evidence that ACT can reduce levels of depression (Zettle & 
Hayes, 1986; Zettle & Raines, 1989; Petersen, 2007) with medium to large effect sizes 
(Forman et al., 2007; Lappalainen et al., 2007). In addition, Bohlmeijer et al. (2011) found 
that an ACT-based early intervention for people with mild to moderate levels of depression 
(total N = 93) was effective in reducing depressive symptomatology. The ACT intervention 
led to statistically significant reduction in depressive symptomatology (as assessed by the 
Center for Epidemiologic Studies Depression Scale; Radloff, 1977), which were maintained 
at the three-month post-baseline. 
 
There is growing research interest in the application of ACT to difficulties faced by 
individuals experiencing psychosis. Randomised controlled trials (RCTs) have shown that 
individuals receiving ACT demonstrated significantly lower belief in positive symptoms 
compared to Treatment As Usual (TAU) (Bach & Hayes, 2002; Gaudiano & Herbert, 2006). 
Bach and Hayes (2002) also found that the ACT interventions were associated with 
significantly reduced rates of rehospitalization at follow-up compared to a TAU. In addition, a 
cross-sectional study of patients with psychotic-spectrum disorders conducted by Shawyer et 
al. (2007) reported that greater acceptance of voices was associated with lower depression, 
greater confidence in coping with command hallucinations, and greater subjective quality of 
life. Recently, we completed a feasibility randomised controlled trial which found that ACT 
reduced depression in individuals with psychosis to a significantly greater extent than did 
TAU (White et al., 2011).  
 
However, these preliminary treatment signals need further scrutiny in order to more precisely 
specify what additional benefit can be gained from ACT versus standard treatment 
approaches. Gaudiano (2006) called for greater emphasis to be placed on examining the 
clinical significance of symptomatic outcome in trials of psychological interventions for 
psychosis. In line with this call, the authors of the current paper identified participants 
recruited to the White et al. (2011) RCT who had clinically important levels of depression at 
baseline assessment.  Post-hoc analyses were performed to determine if there were clinically 
significant changes in depression, anxiety, symptoms of psychosis and psychological 
flexibility between baseline and three-month post-baseline assessments. Specifically, we were 
interested to compare whether the proportion of individuals achieving clinically significant 
changes in depression was greater for those randomised to ACT compared to those 
randomised to TAU. 
Method 
Design 
A repeated measures design was employed. Participants were assessed at baseline and then 
again at a point 3-months post-baseline, which was intended to coincide with the end of the 
delivery of the intervention to those in the ACT arm of the study. 
Participants 
Participants in the current study were a subsample of participants recruited to a feasibility 
RCT of ACT for emotional dysfunction following psychosis (ACTp: White et al., 2011); 
please consult the White et al. (2011) paper for further details of the inclusions and exclusion 
criteria. None of the participants in the RCT were acutely unwell with psychosis (as defined 
by a score ≥ 5 on an item of the PANSS Positive Syndrome subscale). Participants were 
included in the current study on the basis that they were presenting with clinically important 
levels of depression at baseline assessment; defined as a score ≥ 8 on the Depression subscale 
of the Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983). Fourteen of 
the 27 individuals recruited to the feasibility RCT met this criterion, eight were subsequently 
randomized to receive ACT and six to TAU; 8 of these individuals were subsequently 
randomized to receive ACT, whereas 6 were randomised to TAU. Case file reviews were 
used to ensure that all participants had an ICD-10 (WHO, 1992) diagnosis of a psychotic 
disorder (i.e., schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional 
disorder, brief psychotic disorder, psychotic disorder NOS), bipolar disorder (with psychotic 
features), or depressive disorder with psychotic symptoms.  
Measures 
The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) is a widely 
used self-report instrument designed as a brief assessment tool of the distinct dimensions of 
anxiety and depression in non-psychiatric populations. Sellwood et al. (2013) have recently 
demonstrated that the internal consistency of the anxiety and depression sub-scales of the 
HADS in a sample of individuals diagnosed with schizophrenia were sufficiently high (α = 
0.86 and α = 0.83 respectively). 
The Positive Scale of Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987): The 
PANSS is a 30-item observer rated scale used to assess the presence and severity of positive 
(e.g. delusions, hallucinatory behaviour) and negative (e.g. blunted affect, emotional with-
drawl) symptoms. Psychometric studies have reported good inter-rater reliability and 
satisfactory internal consistency, construct validity, and concurrent validity in relation to other 
measures of psychopathology (Kay et al., 1988; 1989). Two research assistants who were 
blind to the randomisation procedures completed the PANSS (JMcT and LR). According to 
PANSS accuracy criteria (Kay, 1991; Lambert, 1996), the two raters achieved highly reliable 
ratings on PANSS assessments. 
 
Acceptance and Action Questionnaire – II (AAQ-II; Bond, Hayes, Baer, Carpenter et al., 
2011): The AAQ-II was developed specifically for assessing ACT outcomes. The total score 
provides an indication of psychological inflexibility. Example items include: I worry about 
not being able to control my worries and feelings, and Emotions cause problems in my life. 
The AAQ-II has been shown to demonstrate satisfactory structure, reliability and validity 
(Bond et al., 2011). 
Procedure 
The research procedures were approved by the West of Scotland NHS Research Ethics 
Committee No. 3 (ref: 09/S0701/74), and R&D approval (ref: PN09CP213) granted from 
NHS Greater Glasgow and Clyde NHS. Further details about recruitment of participants to 
the RCT is detailed by White et al. (2011). The ACT intervention was delivered by the lead 
author (RGW) and consisted of up to 10-sessions of individual therapy. The ACT sessions 
incorporated work focusing on the following themes: (1) Distinguishing between different 
types of experience: internal experience vs. 5-sense experience; (2) Recognising how we get 
caught up struggling to move away from suffering; (3) Moving towards our values (4) Getting 
distance between us and our ‘life stories’, (5) Exploring how trying to control difficult mental 
experiences can be part of the problem rather than the solution, (6) Noticing that we can 
notice: focusing on the context in which mental experiences occur rather on the content of 
these experiences, and (7) Exploring worry thoughts associated with psychosis. All therapy 
sessions were recorded and competence and fidelity assessed by an expert in ACT (GM). All 
participants were also free to receive whatever drug treatments, case management, and/or 
additional psychotherapy that the clinical team deemed necessary. Research Assistants 
administering the assessments were blind to treatment allocation. 
Analysis 
In accordance with previous research (e.g. Jacobson and Truax, 1991), clinically significant 
changes on outcome measures were deemed to have been achieved if the following two 
criteria were met: 
1. The change in outcome score was reliable according to the Reliable Change Index 
(RCI) (RCI < -1.96, or > 1.96). 
2. Post-baseline scores fell below clinical cut-off scores. 
Jacobson and Truax’s (1991) method was used to calculate RCI (see: Figure 1) for the HADS 
Depression and Anxiety subscales, Positive and Negative Syndrome Scale and the 
Acceptance and Action Questionnaire-II. These calculations were based on estimates of test-
retest reliability for the:  
 HADS Depression and Anxiety subscales obtained by Herman (1997) (r = 0.85 and 0.84 
respectively);  
 PANSS Positive Syndrome, Negative Syndrome and General Psychopathology subscales 
obtained by Kay et al. (1987) (r = 0.80, 0.68 and 0.60 respectively); 
 AAQ-II obtained by Bond et al. (2011) (r = 0.81). 
Jacobson et al.’s method (1984; 1986; 1988) (see: Figure 2) was used to determine clinically 
significant cut-off scores for the HADS Anxiety and Depression sub-scales and the AAQ-II 
for the participants recruited to this study. This technique is based on the rationale that there is 
a greater likelihood of the participant being in the normative distribution than a clinical 
distribution after treatment. The cut-off points reflect a point where the probability of coming 
from each of the distributions is equal. HADS normative data obtained by Crawford et al. 
(2001) from a non-clinical sample broadly representative of the UK general adult population 
(N = 1792) yielded clinical cut-off scores for the HADS Depression and Anxiety subscales of 
8.07 and 8.66 respectively. These scores were rounded to the nearest whole number so that a 
cut-off of 8 or above indicated clinically important levels of depression, and a score of 9 or 
above indicated clinically important levels of anxiety. Normative data for the AAQ-II (M = 
18.51, SD = 7.05; Bond et al., 2011) produced a value of 21.14, which meant that a score of 
21 or above was used to classify clinically important levels of psychological inflexibility. 
Because the PANSS is not routinely used in normative contexts, the authors elected to define 
clinically cut-off scores for the PANSS on the basis of the median values of the PANSS 
subscales for the sample of participants included in this study (Positive subscale = 11.5; 
Negative subscale = 14.5; General subscale = 30.5). 
Fisher’s Exact Tests (one-tailed) were used to investigate whether the proportion of 
participants in the ACT group achieving clinically significant changes in assessment measures 
was significantly higher than in the TAU group. As an indication of effect size for Fisher’s 
Exact Tests, Odds Ratios were also calculated where possible. 
INSERT FIGURE 1 HERE 
 
INSERT FIGURE 2 HERE 
  
Results 
Table 1 provides information relating to the age/sex of the participants and scores on the 
assessment measures at baseline. There were no significant differences between participants 
receiving ACT and TAU in age. In terms of ethnicity, all of the participants identified as 
being ‘White British’. 
INSERT TABLE 1 
The analyses performed to determine if there were clinical significant changes on the outcome 
measures for the ACT and TAU groups are presented in Tables 2 and 3 respectively. 
INSERT TABLE 2 HERE 
INSERT TABLE 3 HERE 
Table 4 indicates that of the eight individuals who received ACT, six (75%) had clinically 
significant decreases in depression at 3-month post-baseline. This can be compared with only 
one of the six individuals (17%) who received TAU. An Odds Ratio indicated that the odds of 
clinically significant decreases in depression were 15 times more likely in individuals 
receiving ACT compared to TAU. The difference between the two groups in the proportion of 
people achieving clinically significant decreases in depression scores was at the threshold of 
statistical significant (p = 0.05).  
Table 4 also presents data relating to the comparisons made between the ACT and TAU 
groups in the proportion of participants achieving clinical significant change on the AAQ-II, 
HADS-Anxiety subscale, PANSS Positive Syndrome subscale, PANSS Negative Syndrome 
subscale and the PANSS General subscale. None of the difference between the groups on 
these measures were statistical significant. 
 
INSERT TABLE 4 HERE 
Discussion 
 
The current study conducted post-hoc analyses on a subsample of 14 participants presenting 
with clinically important levels of depression at baseline assessment who had originally been 
recruited to a randomised controlled trial (RCT) conducted by White et al. (2011). Unlike the 
original RCT, the current study investigated clinically significant changes in outcome 
measures between baseline and 3-months post-baseline in the participants who received ACT 
(N=8) compared to those receiving TAU (N=6). Compared with participants in the TAU 
group, participants who received ACT were 15-times more likely to achieve clinically 
significant decreases in depression (p = 0.05). There were no significant differences between 
the groups in clinically significant decreases in anxiety, psychological inflexibility, positive 
symptoms, negative symptoms and general levels of psychopathology (p > 0.05).  
 
Only one previous study has examined clinically significant changes in symptoms associated 
with an ACT intervention. In a trial of ACT for psychosis, Gaudiano & Herbert (2006) found 
that 50% of participants in the ACT group reached a clinically significant improvement on 
Brief Psychiatric Rating Scale total score which was a significantly greater proportion than in 
the enhanced treatment as usual group (7%). Participants were recruited to the White et al. 
(2011) feasibility trial on the basis that they were no longer acutely unwell. Consequently, 
only a comparatively small number of participants in the current study had clinically 
significant levels of positive or negative symptoms. As such, it is not surprising that there 
were no significant differences between the ACT and TAU groups in the number of 
participants who had clinically significant decreases in positive and negative symptoms from 
baseline to 3-month post-baseline assessment.  
 
The finding that clinically significant changes in depression can occur in the context of 
psychosis in the absence of marked changes in positive and negative symptoms is consistent 
with previous research evidence suggesting that ‘post-psychotic’ depression emerges 
independently of positive symptom severity, relapse and negative symptoms (Birchwood et 
al., 2000; Iqbal et al., 2000). It has been suggested that depression is more closely associated 
with interpersonal adjustment than severity of psychiatric symptoms (Rocca et al., 2005). 
 
There were a number of limitations with the current study. The number of participants that 
were included was small. In addition, the same therapist delivered the ACT intervention 
across the participants. It may be that the better outcomes noted for the participants receiving 
the ACT intervention were attributable to the therapist rather than the therapy per se. 
Additional research recruiting larger numbers of participants and multiple therapists is 
required to explore whether the findings reported in this study are replicable. Post-hoc 
analyses were conducted in this study. Participants were not recruited and into the White et al. 
(2011) trial on the basis that they had clinically important levels of depression. Therefore the 
randomization procedure may not have adequately controlled for potential biases in group 
allocation.  
 
Conclusions 
 
Depression emerging in the context of psychosis is a common but somewhat neglected issue. 
Despite depression being a limiting factor in the long-term prognosis of individuals, there has 
been an absence of interventions aimed at addressing this issue. The findings from this study 
tentatively suggest that ACT offers promise for bringing about clinically significant changes 
in the depression that people with psychosis can experience, however in light of the 
limitations of the current study further research is required. With this in mind, the authors of 
the current paper are undertaking a randomised controlled trial of ACT for post-psychotic 
depression. 
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Table 1. Information about the age/sex of participants and scores on measures at 
baseline assessment. 
Highlights 
 Depression can impact negatively on quality of life of individuals with 
psychosis. 
 Fourteen participants with depression in the context of psychosis were 
included. 
 Eight participants received ACT and six received treatment as usual. 
 Participants were assessed at baseline and three-months post-baseline. 
 Clinically significant changes in depression were more pronounced in the 
ACT group. 
Table 1. Information about the age/sex of participants and scores on measures at baseline assessment. 
 
Age 
(Median/IQR) 
AAQ-II 
HADS-
Depression 
HADS- 
Anxiety 
PANSS-
Positive 
PANSS-
Negative 
PANSS-
General 
Sex (N) 
        Male Female 
Participants 
receiving ACT  
(N = 8) 
32.50  
(28.0 – 38.75) 
30.00 
(23.00-35.75) 
11.50 
(9.50-13.75) 
11.00 
(5.25-12.75) 
11.00 
(11.00-11.75) 
14.50 
(12.25-19.00) 
30.50 
(28.50-31.75) 
5 3 
Participants 
receiving TAU  
(N = 6) 
34.50 
(24.75 – 47.25) 
34.50 
(26.25-44.50) 
11.00 
(8.75-14.50) 
14.50 
(10.75-18.25) 
15.00 
(11.50-17.25) 
14.50 
(11.50-18.75) 
31.00 
(27.50-36.50) 
5 1 
All Participants (N 
= 14) 
32.5  
(25.5 – 44.5) 
32.00 
(23.00-37.25) 
11.50  
(9.00-14.00) 
12.00  
(15.50) 
11.50  
(11.00-14.50) 
14.50 
(12.00-17.00) 
30.50 
(28.00-33.00) 
10 4 
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Table 2. Information about changes in outcome measures for the ACT Group 
Participant Measure Baseline 3 Month Post-
baseline 
RCI Below 
clinical cut 
off score 3-
months 
Post-
baseline 
Score ≥ the 
baseline 
median at 
baseline 
Score < the 
baseline 
median at 3-
month post-
baseline 
Clinical 
significant 
change 
1 AAQ-II 32 14 -2.68 Yes   Yes 
 HADS Dep 11 2 -6.57 Yes   Yes 
 HADS Anx 4 2 -0.76 Yes   No 
 PANSS Positive 11 8 -1.51  No Yes No 
 PANSS Negative 26 18 -1.77  Yes No No 
 PANSS General 31 22 -2.71  Yes Yes Yes 
2 AAQ-II 30 9 -3.13 Yes   Yes 
 HADS Dep 14 5 -6.57 Yes   Yes 
 HADS Anx 3 1 -0.76 Yes   No 
 PANSS Positive 11 7 -2.01  No Yes No 
 PANSS Negative 13 10 -0.66  No Yes No 
 PANSS General 24 21 -0.90  No Yes No 
3 AAQ-II 21 27 0.90 No   No 
 HADS Dep 11 4 -5.11 Yes   Yes 
 HADS Anx 9 3 -2.37 Yes   Yes 
 PANSS Positive 11 8 -1.51  No Yes No 
 PANSS Negative 20 12 -1.77  Yes Yes No 
 PANSS General 32 24 -2.41  Yes Yes Yes 
4 AAQ-II 38 24 -2.09 No   No 
 HADS Dep 12 3 -6.57 Yes   Yes 
 HADS Anx 12 4 -3.03 Yes   Yes 
 PANSS Positive 13 7 -4.26  Yes Yes Yes 
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 PANSS Negative 15 10 -1.10  Yes Yes No 
 PANSS General 31 21 -3.01  Yes Yes Yes 
5 AAQ-II 23 24 0.15 No   No 
 HADS Dep 13 3 -7.30 Yes   Yes 
 HADS Anx 12 8 -1.52 Yes   No 
 PANSS Positive 9 17 3.02  No  Yes *Yes  
 PANSS Negative 16 9 -1.55  Yes Yes No 
 PANSS General 30 20 -3.01  No Yes No 
6 AAQ-II 30 24 -0.90 No   No 
 HADS Dep 9 8 -0.73 No   No 
 HADS Anx 13 12 -0.38 No   No 
 PANSS Positive 11 10 -0.50  No Yes No 
 PANSS Negative 14 8 -1.32  No Yes No 
 PANSS General 30 25 -1.51  No Yes No 
7 AAQ-II 37 30 -1.04 No   No 
 HADS Dep 15 9 -4.38 No   No 
 HADS Anx 15 10 -1.89 No   No 
 PANSS Positive 12 17 2.51  Yes  No No  
 PANSS Negative 12 10 -0.44  No No No 
 PANSS General 33 35 0.62  Yes No No 
8 AAQ-II 23 8 -2.23 Yes   Yes 
 HADS Dep 9 1 -5.84 Yes   Yes 
 HADS Anx 10 4 -2.27 Yes   Yes 
 PANSS Positive 11 7 -2.01  No Yes No 
 PANSS Negative 12 10 -0.44  No Yes No 
 PANSS General 28 18 -3.01  No Yes No 
*Clinically significant increase 
 
 
Key for Tables: 
AAQ-II = Acceptance and Action Questionnaire 
HADS Dep = Hospital Anxiety and Depression Scale – Depression Subscale 
HADS Anx = Hospital Anxiety and Depression Scale – Anxiety Subscale 
PANSS Positive = Positive and Negative Syndrome Scale – Positive Symptom Scale 
PANSS Negative = Positive and Negative Syndrome Scale – Negative Symptom Scale 
PANSS General = Positive and Negative Syndrome Scale – General Psychopathology Scale 
 
Table 3. Information about changes in outcome measures for the TAU Group 
Participant Measure Baseline 3 Month Post-
baseline 
RCI Below 
clinical cut 
off score 3-
months 
Post-
baseline 
Score ≥ the 
baseline 
median at 
baseline 
Score < the 
baseline 
median at 3-
month post-
baseline 
Clinical 
significant 
change 
1 AAQ-II 34 25 -1.34 No   No 
 HADS Dep 10 11 0.73 No   No 
 HADS Anx 11 9 -0.76 No   No 
 PANSS Positive 21 14 -3.52  Yes No No 
 PANSS Negative 30 22 -1.77  Yes No No 
 PANSS General 38 20 -5.42  Yes Yes Yes 
2 AAQ-II 35 33 -0.30 No   No 
 HADS Dep 12 12 0.00 No   No 
 HADS Anx 12 13 0.38 No   No 
 PANSS Positive 10 8 -1.01  No Yes No 
 PANSS Negative 15 19 0.88  Yes No No 
 PANSS General 33 36 0.90  Yes No No 
3 AAQ-II 32 35 0.30 No   No 
 HADS Dep 14 8 -4.38 No   No 
 HADS Anx 17 14 -1.14 No   No 
 PANSS Positive 12 11 -0.50  Yes Yes No 
 PANSS Negative 10 9 -0.22  No Yes No 
 PANSS General 29 24 -1.51  No Yes No 
4 AAQ-II 49 - - -   - 
 HADS Dep 16 9 -4.58 No   No 
 HADS Anx 19 14 -1.89 No   No 
 PANSS Positive 16 22 3.02  Yes No No 
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 PANSS Negative 14 18 0.88  No No No 
 PANSS General 36 49 3.92  Yes No No 
5 AAQ-II 43 34 -1.34 No   No 
 HADS Dep 9 8 -0.73 No   No 
 HADS Anx 18 18 0.00 No   No 
 PANSS Positive 16 13 -1.51  Yes No No 
 PANSS Negative 15 10 -1.10  Yes Yes No 
 PANSS General 26 31 1.51  No Yes No 
6 AAQ-II 9 28 2.84 No   *Yes 
 HADS Dep 8 5 -2.19 Yes   Yes 
 HADS Anx 10 13 1.14 No   No 
 PANSS Positive 14 9 -2.51  Yes Yes Yes 
 PANSS Negative 12 15 0.66  No No No 
 PANSS General 28 20 -2.41  No Yes No 
*Clinically significant increase 
 
 
 
Key for Tables: 
AAQ-II = Acceptance and Action Questionnaire 
HADS Dep = Hospital Anxiety and Depression Scale – Depression Subscale 
HADS Anx = Hospital Anxiety and Depression Scale – Anxiety Subscale 
PANSS Positive = Positive and Negative Syndrome Scale – Positive Symptom Scale 
PANSS Negative = Positive and Negative Syndrome Scale – Negative Symptom Scale 
PANSS General = Positive and Negative Syndrome Scale – General Psychopathology Scale 
 
Table 4. Information about the proportion (%) of participants achieving clinical 
significant change on the outcome measures  
Outcome 
Measure 
Proportion (%) 
of ACT group 
achieving 
clinically 
significant 
change 
Proportion (%) 
of TAU group 
achieving 
clinically 
significant 
change 
Odds Ratio P-value 
HADS Dep 6/8 (75%) 1/6 (17%) 15 p = 0.05 
HADS Anx 3/6 (50%) 0/6 (0%) N/A p > 0.05 
AAQ-II 3/8 (38%) 0/4 (0%) N/A p > 0.05 
PANSS Positive  1/2 (50%) 1/5 (20%) 4 p > 0.05 
PANSS 
Negative  
0/4 (0%) 0/3 (0%) N/A p > 0.05 
PANSS General  3/4 (75%) 1/3 (33%) 6 p > 0.05 
 
Key for Tables: 
AAQ-II = Acceptance and Action Questionnaire 
HADS Dep = Hospital Anxiety and Depression Scale – Depression Subscale 
HADS Anx = Hospital Anxiety and Depression Scale – Anxiety Subscale 
PANSS Positive = Positive and Negative Syndrome Scale – Positive Symptom Scale 
PANSS Negative = Positive and Negative Syndrome Scale – Negative Symptom 
Scale 
PANSS General = Positive and Negative Syndrome Scale – General Psychopathology 
Scale 
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Figure 1. The equation for calculating Reliable Change Index 
 
      
     
            
 
 
Where X1 = baseline score; X2 = 3-month post-baseline score; S1 = the standard 
deviation at baseline; and rxx = the test-retest reliability  
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Figure 2. The equation for calculating Cut-off Scores 
 
 
        
                   
     
 
 
Where X1, S1, X2, S2 specify the means and standard deviations of the participants with 
psychosis and a normative sample respectively. 
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